Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v2.4.0.8
Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 93 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Operating expenses:      
Research and development $ 4,487 $ 5,974 $ 72,178
General and administrative 2,095 2,484 28,472
In-process research and development 0 0 21,749
Loss from operations (6,582) (8,458) (122,399)
Interest income 178 76 1,203
Interest expense (966) (476) (6,842)
Other income 0 0 733
Warrant expense 0 0 (1,407)
Net loss (7,370) (8,858) (128,712)
Common Stock dividend to Series A Convertible Preferred Stockholders 0 0 (5,861)
Net loss attributed to Common Stockholders $ (7,370) $ (8,858) $ (134,573)
Basic and diluted net loss per common share $ (0.21) $ (0.35)  
Weighted average common shares outstanding—basic and diluted 35,900,596 25,182,369